Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 68Ga-LNC1007 in Healthy Volunteers and Solid Tumor Patients
NCT06463782Phase 1Completed
- Sponsor
- Yantai Lannacheng Biotechnology Co., Ltd.
- Start
- Jan 2025
- Primary completion
- May 2025
- Modality
- Radiopharmaceutical, Diagnostic Agent, CA (Contrast Agent)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-LNC1007 in solid tumor, sponsored by Yantai Lannacheng Biotechnology Co., Ltd. Primary endpoint: Safety of 68Ga-LNC1007 Injection at 2 years. Started Jan 2025; status: completed.
02
Drugs
68Ga-LNC1007
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06463782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463782.